Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and interna…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Transactions 2026-06-01 Financing
Report of exempt distribution (45-106F1).pdf
Results 2026-05-29
Interim MD&A - English.pdf
Results 2026-05-29
Interim financial statements/report – English.pdf
Results 2026-05-29
Theralase(R) Releases Q1 2026 Financial Statements
News release - English.pdf
Transactions 2026-05-27 Financing
Preliminary short form prospectus – English.pdf
Transactions 2026-05-25 Financing
Theralase Technologies Inc. Closes Brokered and Non-Brokered Private Placement Offerings for Gross Proceeds of C$4,761,669
Material change report - English.pdf
Transactions 2026-05-25 Financing
Material document(s).pdf
Ownership 2026-05-25
Bruder, Randall bought +$5k
Insider trading – 2026-05-25
1 insider · +$5k net
Ownership 2026-05-24
Lbiati, Kaouthar bought +$17k
Insider trading – 2026-05-24
1 insider · +$17k net
Transactions 2026-05-20 Financing
Theralase(R) Closes C$4.8 Million Offering
News release - English.pdf
Ownership 2026-05-20
4 insiders · +$14k net
Insider trading – 2026-05-20
4 insiders · +$14k net
Results 2026-05-07
Annual information form - English.pdf
Transactions 2026-05-06 Financing
Theralase(R) Announces $4 Million Brokered LIFE Offering
News release - English.pdf
Results 2026-05-04
Annual MD&A - English.pdf
Results 2026-05-04
Audited annual financial statements – English.pdf
Results 2026-05-04
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
News release - English.pdf
Transactions 2026-04-27 Financing
Theralase Technologies Inc. Closes Non-Brokered Private Placement and Secures $1,000,000 Revolving Line of Credit
Material change report - English.pdf
Transactions 2026-04-20 Financing
Report of exempt distribution (45-106F1).pdf
Results 2026-04-13
Theralase® Reports Complete Response with X-Ray-Activated Rutherrin® in Muscle Invasive Bladder Cancer Preclinical Study
News release - English.pdf
Transactions 2026-04-10 Financing
Theralase(R) Closes $CAN 2.66 Million Financing
News release - English.pdf
Ownership 2026-04-10
Perraton, Matthew Thomas bought +$10k
Insider trading – 2026-04-10
1 insider · +$10k net
Transactions 2026-03-25 Financing
Theralase Technologies Inc. Closes Non-Brokered Private Placement of Units for Aggregate Gross Proceeds of Approximately $1,100,000
Material change report - English.pdf
News 2026-03-17
Report of exempt distribution (45-106F1).pdf
News 2026-03-17
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
News release - English.pdf
Transactions 2026-03-10 Financing
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
News release - English.pdf
News 2026-03-09
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
News release - English.pdf
News 2026-03-02
Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon
News release - English.pdf
News 2026-02-20
Theralase Technologies Inc. Announces Interim Clinical Data on TLD-1433 for Bladder Cancer to be Presented at EAU26
News release - English.pdf
News 2026-02-17
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
News release - English.pdf
News 2026-02-10
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
News release - English.pdf
News 2026-02-04
Theralase(R) Provides Update on Bladder Cancer Clinical Study
News release - English.pdf
Results 2026-02-02
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
News release - English.pdf
Transactions 2026-01-26 M&A
Theralase and Ferring Pharmaceuticals Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Material change report - English.pdf
Transactions 2026-01-26
Material document(s).pdf
Transactions 2026-01-12 M&A
Ferring Pharmaceuticals and Theralase Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
News release - English.pdf
Transactions 2026-01-08 Financing
Theralase Technologies Inc. Closes Non-Brokered Private Placement
Material change report - English.pdf
News 2026-01-06
Report of exempt distribution (45-106F1).pdf
Transactions 2025-12-23 Financing
Theralase(R) Closes $1.3M Non-Brokered Private Placement
News release - English.pdf
News 2025-12-19
Letter from former auditor.pdf
News 2025-12-19
Notice.pdf
News 2025-12-19
Letter from successor auditor.pdf
Transactions 2025-12-12 Financing
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
News release - English.pdf
News 2025-11-24
Offering document - English.pdf
Transactions 2025-11-24 Financing
Theralase® Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
News release - English.pdf
News 2025-11-10
News release - English.pdf
Results 2025-11-10 Financials
Interim MD&A - English.pdf
Results 2025-11-10 Financials
Interim financial statements/report – English.pdf
News 2025-11-03
News release - English.pdf
News 2025-09-24
News release - English.pdf
News 2025-08-29
News release - English.pdf
Results 2025-08-26 Financials
Interim MD&A - English.pdf
Results 2025-08-26 Financials
Interim financial statements/report – English.pdf
News 2025-08-26
News release - English.pdf
News 2025-08-05
Material change report - English.pdf
News 2025-08-05
Report of exempt distribution (45-106F1).pdf
Ownership 2025-07-31
Hachey, Kristina Maria bought +$26k
Insider trading – 2025-07-31
1 insider · +$26k net
News 2025-07-28
News release - English.pdf
News 2025-07-09
Report of exempt distribution (45-106F1) (amended).pdf
News 2025-07-07
Material change report - English.pdf
News 2025-07-01
News release - English.pdf
News 2025-06-23
Report of exempt distribution (45-106F1).pdf
Ownership 2025-06-23
Lbiati, Kaouthar bought +$34k
Insider trading – 2025-06-23
1 insider · +$34k net
News 2025-06-17
News release - English.pdf
Ownership 2025-06-17
2 insiders · +$110k net
Insider trading – 2025-06-17
2 insiders · +$110k net
Ownership 2025-03-20
Lbiati, Kaouthar bought +$10k
Insider trading – 2025-03-20
1 insider · +$10k net
Ownership 2025-03-12
Perraton, Matthew Thomas bought +$12k
Insider trading – 2025-03-12
1 insider · +$12k net
Ownership 2025-03-11
3 insiders · +$36k net
Insider trading – 2025-03-11
3 insiders · +$36k net